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AbstrAct
Human papillomavirus (HPV) causes cervical cancer and a large fraction of head 
and neck squamous cell carcinomas (HNSCC). Cidofovir (CDV) proved efficacious in 
the treatment of several HPV-induced benign and malignant hyper proliferations. To 
provide a better insight into how CDV selectively eradicates transformed cells, HPV+ 
and HPV− cervical carcinoma and HNSCC cell lines were compared to normal cells for 
antiproliferative effects, CDV metabolism, drug incorporation into cellular DNA, and 
DNA damage. Incorporation of CDV into cellular DNA was higher in tumor cells than in 
normal cells and correlated with CDV antiproliferative effects, which were independent 
of HPV status.  Increase in phospho-ATM levels was detected following CDV exposure 
and higher levels of γ-H2AX (a quantitative marker of double-strand breaks) were 
measured in tumor cells compared to normal cells. A correlation between DNA damage 
and CDV incorporation into DNA was found but not between DNA damage and CDV 
antiproliferative effects. These data indicate that CDV antiproliferative effects result 
from incorporation of the drug into DNA causing DNA damage. However, the anti-
tumor effects of CDV cannot be exclusively ascribed to DNA damage. Furthermore, 
CDV can be considered a promising broad spectrum anti-cancer agent, not restricted 
to HPV+ lesions.
IntroductIon
Human papillomaviruses (HPVs) are double-
stranded DNA viruses with a small genome of about 8 kbp. 
HPVs can induce benign (low-risk types) and malignant 
(high-risk types) lesions. High-risk HPVs are involved in 
almost all cases of cervical carcinoma, a number of other 
anogenital cancers and an increasing amount of head and 
neck squamous cell carcinomas (HNSCC) [1–3]. 
HPVs have a tropism for epithelial cells and cancer 
progression is associated with a persistent infection caused 
by a high-risk HPV type (such as HPV type 16, 18, 31, 
33 and 45). When an HPV infection evolves into cancer, 
the episomal viral DNA frequently becomes integrated 
into the host-cell DNA resulting in a loss of viral gene 
expression, except for the genes encoding the HPV E6 
and E7 oncoproteins [4]. These two oncoproteins are 
responsible for cell transformation and immortalization 
[5]. Among several functions, E6 causes degradation 
of the tumor suppressor p53 [6] while one of the most 
important functions of E7 is the association with the 
retinoblastoma family of proteins (pRB), abrogating DNA 
repair and maintenance of genomic integrity. In contrast 
to normal cells, tumor cells are often unable to repair 
DNA damage because of defects in their DNA damage 
response mechanisms [7]. Upon double-strand breaks 
(DSBs), the ataxia telangiectasia mutated (ATM) protein 
is activated by phosphorylation of a serine at position 
1981 which causes monomerization and transport of ATM 
to the sites of DNA damage. The stabilization of ATM at 
DNA damage sites is required for a proper DNA damage 
response [8]. Phospho-ATM can be dephosphorylated 
by protein phosphatase 2 (PPA2) and by wild-type p53-
induced phosphatase 1 (Wip1). These phosphatases 
prevent illicit activation of the DNA damage response in 
the absence of damage and allow rapid cessation of the 
signal once DNA damage is repaired [9]. Activated ATM 
is responsible for the phosphorylation of the H2A histone 
family member X (H2AX) protein at serine 139 resulting 
in γ-H2AX (phosphorylated-H2AX) foci at the sites of 
DNA damage. Phosphorylation of H2AX was shown to be 
important to recruit repair proteins to DNA damage sites 
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and γ-H2AX is considered a sensitive and quantitative 
indicator of DSBs [10].
Although there are effective prophylactic vaccines 
available for HPV, treatment of HPV infections remains a 
challenge [11]. HPV vaccination is not applied worldwide 
and generally only adolescent women are vaccinated, 
leaving men, relatively older women and non-vaccinated 
populations unprotected [12]. Current treatment of early 
stage cervical cancer consists of surgical removal of the 
cervical cone (conization). Hysterectomy with radio- and/
or chemotherapy is the treatment of choice for women 
with invasive cervical cancer [13]. HNSCC patients are 
currently treated by either surgery or a combination of 
chemo- and radiotherapy [14]. These interventions are 
generally effective although a substantial morbidity and 
disease recurrence are described [15, 16]. 
Cidofovir [(CDV), [(S)-1-[3-hydroxy-2-
(phosphonomethoxy)propyl]cytosine], HPMPC, Vistide®] 
is an acyclic nucleoside phosphonate (ANP) known for 
its broad-spectrum antiviral activity against DNA viruses. 
CDV was approved by the FDA for the treatment of 
cytomegalovirus (CMV) retinitis in AIDS patients [17]. 
CDV also proved to be efficacious in patients suffering 
from HPV-associated diseases including severe laryngeal 
papillomatosis, anogenital papillomavirus infections and 
cervical intraepithelial neoplasia stages 2+ and 3 [18–22]. 
CDV was shown to have antiproliferative properties 
against HPV+ cervical carcinoma and HPV- transformed 
cell lines [23]. Moreover, CDV has not only been 
demonstrated to improve the pathology caused by the 
growth of HPV+ xenografts in athymic nude mice [24], 
but also against a number of HPV- malignancies in vivo 
like glioblastoma, hemangiosarcoma and nasopharyngeal 
carcinoma [25–28].
CDV requires two phosphorylation steps in order 
to be active. The first phosphorylation is catalyzed 
by the cytosolic UMP-CMP kinase, producing CDV-
monophosphate (CDVp) which is then phosphorylated 
by a nucleoside diphosphate kinase, pyruvate kinase 
or creatine kinase to the diphosphate form (CDVpp). 
The intracellular depot form of CDV, cidofovir 
monophosphocholine (CDVp-choline) is formed by 
choline-phosphate cytidylyltransferase [29–31]. CDVpp 
is the active metabolite and can be incorporated into DNA 
instead of the natural substrate dCTP [17]. 
The antiproliferative effects of CDV against HPV+ 
cervical cancer cell lines were reported for the first time 
in 1998 [23]. In contrast to other chemotherapeutic 
agents, inhibition of cell growth by CDV increased in 
function of time [23]. Today, the molecular mechanisms 
underlying the selectivity of CDV for transformed cells 
are not completely understood. To investigate the selective 
effects of CDV for tumor cells compared to normal cells, 
our group performed a comprehensive analysis of gene 
expression profiling by means of microarray in cervical 
cancer cells [SiHa (HPV16+) and HeLa (HPV18+)], 
immortalized keratinocytes (HaCaT) and primary human 
keratinocytes (PHKs), exposed or not to CDV. Functional 
classification of differentially expressed genes, using 
Ingenuity Pathway Analysis software, was performed to 
identify functional categories and molecular pathways 
changed following CDV exposure in transformed cells 
versus normal cells. Cell cycle regulation and DSB repair 
mechanisms, such as ATM signaling and DSB repair by 
homologous recombination were found to be activated in 
CDV-exposed PHKs but not in transformed cells. These 
data pointed to the generation of DSBs following CDV 
exposure [32]. Furthermore, previous results revealed 
that CDV selectivity for HPV transformed cells may be 
based on differences in replication rates and on CDV 
incorporation into genomic DNA between cancer cells 
(SiHa, HeLa and HaCaT) and normal cells (PHKs) [32]. 
Here we have demonstrated at the protein level that 
CDV induces DSBs in different tumor cell types. 
Induction of DNA damage by CDV was compared with 
antiproliferative effects and drug incorporation into 
DNA in our studies using both high-risk HPV+ and HPV− 
HNSCC and cervical carcinoma cell lines as well as 
normal cells. We demonstrate here a correlation between 
DNA incorporation of CDV and DNA damage and 
between CDV incorporation and antiproliferative effects 
but not between DNA damage and CDV antiproliferative 
effects. Our findings also support the applicability of CDV 
as a broad spectrum antitumor agent against both HPV+ 
and HPV− tumors. 
results
Antiproliferative effects of cdV on HPV+ and 
HPV− tumor cells and normal cells
The antiproliferative effects of CDV were evaluated 
in HPV+ and HPV− transformed cells as well as normal 
cells. Before performing these experiments, the HPV 
positivity and negativity of all cell lines was confirmed by 
means of PCR with specific primers for the detection of 
HPV16, HPV18 and HPV33. All cells were tested for the 
three HPV types and the HPV16 positivity of SiHa, Caski, 
SCC-147, UM-SCC-47, UD-SCC-2 and UM-SCC-104 
was confirmed. HeLa cells proved to be HPV18+ and 
CK1 and UT-SCC-45 were HPV33+. The other cell lines 
(i.e. C33A, SCC-9, SCC-4, SCC-120, UM-SCC-38 and 
HaCaT) and the normal human diploid cells (i.e. HEL, 
PHK and PET) were negative for HPV16, HPV18 or 
HPV33.
The antiproliferative effects of CDV on the different 
cells were measured at 3, 5, 7 and 10 days post-exposure 
to CDV (Figure 1A). First, the CC50 values at 3 days 
post-treatment were compared for the different cell lines 
(Figure 1B). Lower CC50 values at 3 days post-treatment 
were observed for most of the transformed cell lines in 
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comparison with normal cells, showing the selectivity of 
CDV for tumor cells. SiHa, CK1, HaCaT and SCC-120 
were significantly more sensitive to CDV after 3 days of 
treatment than PHK, HEL and PET cells. Also HeLa cells, 
SCC-147, UT-SCC-45, SCC-4, SCC-9 and C33A showed 
lower CC50 values than PET and HEL cells, but they were 
not significantly different from PHKs. UD-SCC-2, UM-
SCC-47 and Caski showed a difference in CC50’s with 
PET cells 3 days post-treatment but not with the two 
other normal cells. UM-SCC-104 and UM-SCC-38 had 
a sensitivity to CDV comparable to that of normal cells.
Our results showed that the antiproliferative activity 
of CDV significantly increased over time from day 3 to 
day 10 post-treatment in all the cell lines tested, except for 
Caski and SCC-120, where the increase was not significant 
(Figure 1A).
After 7 days of treatment, CDV inhibited the growth 
of most of the cancer cell lines (SiHa, CK1, SCC-147, 
UM-SCC-47, UT-SCC-45, UM-SCC-104, UM-SCC-38, 
C33A, HaCaT, SCC-120, SCC-4, SCC-9) in comparison 
with HEL and PET cells (Figure 1B). However, no 
significant differences in CC50 values between these tumor 
cell lines and PHKs were observed. The proliferation of 
HeLa and UD-SCC-2 cells was significantly reduced by 
CDV at 7 days post-treatment compared to PET cells, but 
not compared to PHKs and HEL cells. The CC50 values of 
Caski were not different from those of normal cells at 7 
days post-treatment.
The doubling time (DT) of the different cells was 
calculated to evaluate the in vitro growth rate of the 
cell lines in the absence of CDV. As cancer cells are by 
definition fast proliferating cells, the tumor cell lines 
showed shorter doubling time than normal cells (Table 1). 
A significant difference in doubling time was observed 
between PET cells and all the cancer cells while PHK 
showed a significantly longer doubling time than the 
tumor cells except for SCC-147, UM-SCC-104 and UD-
SCC-2. Differences in doubling time between tumor cells 
and HEL cells were observed for most of the tumor cells 
except for SCC-147, UM-SCC-104, UT-SCC-45, UD-
SCC-2 and SCC-4. 
A correlation between doubling time and CC50 
values of all tested cell types, including normal cells, was 
observed at day 3 (p < 0.001), 5 (p < 0.05), 7 (p < 0.01) 
and 10 (p < 0.05) post-treatment, indicating that the 
growth of slow proliferating cells is less inhibited by CDV 
than that of fast proliferating cells (Figure 2A). When 
the normal cells were excluded from the analysis, only a 
significant correlation between CC50 values and doubling 
time was observed after 3 days of treatment (p < 0.01) 
but not at later time points (Figure 2B), indicating that the 
sensitivity of tumor cells to CDV does not depend on their 
growth rate at the later time points. 
Based on these results, representative cell lines were 
selected for further studies on CDV metabolism, drug 
incorporation into DNA and induction of DNA damage 
in order to investigate the antiproliferative mechanisms 
of CDV. Cervical cancer cell lines were selected to have 
a representative HPV16+ and HPV18+ cell line (SiHa 
and HeLa, respectively) and an HPV− cell line (C33A). 
One HPV16+ (SCC-147) and one HPV− (SCC-120) 
HNSCC were also selected as well as the spontaneously 
transformed keratinocytes (HaCaT). The normal cells 
(PHKs, PET and HEL) were included as controls.
cdV metabolism and incorporation into dnA
CDV metabolism and incorporation into DNA were 
examined following incubation of the different cell types 
with radiolabeled compound. The CDV metabolites in 
the methanol soluble fraction were separated by HPLC 
analysis (Table 2). In all cell types, non-metabolized CDV 
and its depot form (i.e. CDVp-choline) were detected at 
higher levels than the two phosphorylated metabolites 
(i.e. CDVp and CDVpp). CDVp was less abundant than 
CDVpp in all the cell types except for PET cells. It 
needs to be mentioned that the amount of CDVpp in the 
methanol soluble fraction represents the free metabolite 
and therefore, does not include CDV incorporated into 
cellular DNA. 
A comparison of the sum of all metabolites in tumor 
cells versus normal cells showed higher amounts in PHKs 
and PET cells than in tumor cell lines (i.e. SiHa, HeLa, 
C33A, HaCaT, SCC-120 and SCC-147) and HEL cells. 
HaCaT had the lowest level of total metabolites among all 
the tested cell types.
To determine the level of CDV incorporated into 
DNA, the radioactivity recovered from the methanol 
insoluble fraction was measured. Normal cells had lower 
amounts of CDV incorporated into DNA than the tested 
tumor cells, however the differences were statistically 
non-significant (Table 2). In Table 3, the incorporation 
of CDV in tumor cells relative to normal cells is shown. 
Tumor cells incorporated more CDV than PHKs (1.1 
to 2.1 folds), HEL cells (1.1 to 2.2 folds) and PET cells 
(2.1 to 4.1 folds). For all the tested cell types, including 
normal cells, a negative correlation (p < 0.05) between 
doubling time and CDV incorporation into DNA was 
observed at day 3 post-treatment, indicating that fast 
proliferating cells incorporate more CDV than cells with a 
slower growth rate (Figure 3).
We also analyzed whether a correlation between 
CDV incorporation into genomic DNA and CC50 values 
exists since the latter parameter estimates the net outcome 
of CDV treatment in terms of antiproliferative effects. A 
negative correlation (p < 0.05) between CDV incorporation 
and CC50’s was observed (Figure 4) revealing that the cells 
that are more prone to CDV antiproliferative effects (i.e. 
with low CC50 values) had the highest CDV incorporation 
into the genomic DNA. 
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Figure 1: Antiproliferative effects of cdV. CC50 values in function of days post treatment. Cells seeded in a 96 well plate were treated 
after 24 h with dilutions of CDV ranging from 0.05 µg/ml to 200 µg/ml. At 3, 5, 7 and 10 days post treatment, cells were counted with a 
Coulter counter to calculate CC50 values. The CC50 value is the concentration of CDV needed to inhibit cell growth by 50%. HPV
+ cell lines 
are indicated in blue, HPV- in green and the normal cells in pink. Cervical cancer cell lines are indicated by closed symbols and HNSCC by 
open symbols. Values are shown as mean of minimum 3 experiments per cell line and SEM. (A) CC50 values in function of day 3, 5, 7 and 
10 post-treatment. (b) CC50 values in function of day 3 and 7 post-treatment.
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table 1: doubling time of the cells
cells (HPV+) dt ± seM cells (HPV−) dt ± seM Primary cells dt ± seM
siHa 21.98 ± 1.08 c33A 27.69 ± 4.32 PHK 60.52  ± 5.34
caski 24.92 ± 1.26 Hacat 24.54 ± 2.65 Hel 52.04  ± 6.73
Hela 24.06 ± 1.02 scc-120 27.76 ± 2.15 Pet 110.47  ± 11.21
cK1 25.79 ± 1.10 scc-4 40.71 ± 2.11
scc-147 43.42 ± 6.12 scc-9 33.89 ± 2.08
uM-scc-47 37.63 ± 1.47 uM-scc-38 35.54 ± 3.11
uM-scc-104 62.07 ± 5.43
ut-scc-45 38.52 ± 3.95
ud-scc-2 43.31 ± 5.55
Mean doubling time (DT), in hours, and SEM of the cell lines. At least 3 experiments were performed per cell line. Untreated 
cells were seeded in 96 well plates and counted at the same time points as for the antiproliferative experiments. DT was 
calculated with the formula: DT = (t2–t1)/(log2N2−log2N1), where t1 and t2 are the times (hours) at which the cells were counted, 
and N1 and N2 are the cell numbers at times t1 and t2.
Figure 2: correlation between doubling time and antiproliferative effects of cdV at days 3, 5, 7 and 10. Pearson 
correlation was made between DT and CC50 values. HPV
+ cell lines are indicated in blue, HPV− in green and the normal cells in pink. 
Cervical cancer cell lines are indicated by closed symbols and HNSCC by open symbols. (A) All the cell lines. (b) Tumor cell lines with 
exclusion of the normal cells.
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dnA damage signaling after cdV treatment 
To investigate DNA damage induction by CDV, the 
activation of ATM was measured at different time points 
post-exposure to CDV. Western blot analysis showed that 
CDV treatment did not increase or decrease the amount of 
total ATM except for a lower expression of ATM at day 7 
in SiHa cells and at day 3 in PET cells (Figures 5 and 6).
Importantly, phospho-ATM (activated ATM) levels 
were elevated in all CDV treated cells compared to 
untreated cells at almost all time points (Figures 5 and 7). 
A significant enhancement of phospho-ATM was seen 
after 3, 5 and 7 days post-CDV exposure in transformed 
cell lines (except for C33A in which ATM was not 
activated after 3 days post-treatment) and in the normal 
cells (i.e. PHK, HEL and PET).
table 2: cdV metabolites and cdV incorporation into genomic dnA
siHa Hela scc-147 scc-120 Hacat c33A PHK Pet Hel
[pmol/10e6 cells]
Methanol-soluble fraction
CDVp-choline 155.84 ± 12.03 94.42 ± 5.89 154.79 ± 8.23 183.84 ± 22.56 54.03 ± 9.21 111.21 ± 27.99 983.77 ± 253.66 573.34 ± 147.20 170.53 ± 31.87
CDV 200.35 ± 57.03 137.08 ± 54.41 234.96 ± 80.03 153.94 ± 33.44 63.58 ± 14.04 135.63 ± 19.07 421.12 ± 56.83 348.27 ± 118.32 132.52 ± 32.60
CDVp 52.22 ± 5.26 23.84 ± 4.67 39.4 ± 9.89 39.77 ± 5.25 22.58 ± 13.35 40.02 ± 7.43 268.48 ± 174.84 120.72 ± 17.37 54.88 ± 6.49
CDVpp 74.98 ± 8.46 63.83 ± 26.50 90.09 ± 10.43 78.16 ± 11.83 28.53 ± 5.5 61.07 ± 17.92 409.61 ± 85.99 118.40 ± 29.54 124.06 ± 24.85
sum of metaboites 483.39 ± 29.57 319.17 ± 30.49 519,2 ± 40.86 455.71 ± 21.18 168.72 ± 11.07 347.93 ± 19.51 2082.98 ± 162.43 1160.73 ± 95.97 481.99 ± 26.16
CDV incorporation 133.02 ± 47.37 67.91 ± 23.05 76.33 ± 22.96 79.01 ± 22.94 91.35 ± 24.38 74.08 ± 23.96 63.09 ± 9.47 32.53 ± 5.54 59.26 ± 15.51
Radiolabeled CDV (10 µCi) was added to the cells to a final concentration of 50 µg/ml and 3 days later a methanol extraction 
was performed. CDV metabolites in the methanol soluble fraction were separated by means of HPLC. Methanol insoluble 
fractions were digested with NaOH and the amount of CDV incorporated into genomic DNA was measured with a scintillation 
counter. Mean CDV incorporation and metabolites of at least 4 experiments and SEM are given in pmol per million cells.
table 3: cdV incorporation in the tumor cells versus normal cells
ratio of cdV incorporation between tumor cells and normal cells
cell line PHK Hel Pet
siHa 2.1 2.2 4.1
Hela 1.1 1.1 2.1
scc-147 1.2 1.3 2.3
scc-120 1.3 1.3 2.4
c33A 1.2 1.2 2.3
Hacat 1.4 1.5 2.8
CDV-incorporation in the tumor cells, relative to the normal cells. Tumor cells are shown in the left column and are compared 
to each of the three normal cells (PHK, HEL and PET).
Figure 3: correlation between doubling time and cdV incorporation at day 3 post infection. Pearson correlation was 
calculated between DT and incorporation of CDV into genomic DNA of the cells. HPV+ cell lines are indicated in blue, HPV− in green and 
the normal cells in pink. Cervical cancer cell lines are indicated by closed symbols and HNSCC by open symbols.
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dnA damage induced by cdV by means of 
γ-H2AX analysis
The activation of ATM in CDV treated cells 
gives a good indication of the induction of DSBs by 
CDV. However, ATM-activation is not correlated with 
the amount of DSBs [33]. Therefore, quantification of 
DSBs was performed using a flow cytometric assay that 
measures γ-H2AX (i.e. H2AX phosphorylated at S139 by 
ATM), which is considered a sensitive marker of DSBs.
Because SiHa cells had the lowest CC50 values 
among all tested cells, the induction of DSBs by different 
concentrations of CDV was determined in SiHa cells 
after 3 days of drug exposure. The percentage of cells 
with DNA damage increased in function of the CDV 
concentration (1 µg/ml to 100 µg/ml) (Figure 8A). Based 
Figure 4: correlation between cc50 values and cdV incorporation at day 3 post-infection. Correlation between CC50 
values and CDV incorporation was evaluated with the Pearson correlation coefficients. A linear regression line was drawn. 
Figure 5: Western blot analysis of dnA damage signaling. Protein extracts were obtained at 3, 5 and 7 days of no treatment 
or treatment with 50 µg/ml CDV. Afterwards, Western blotting was performed. Representative Western blots for each cell line after 
immunoblotting with ATM and phospho-ATM are shown. Actin was used as a loading control.
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on these data, CDV concentrations of 5 and 50 µg/ml were 
used to evaluate DNA damage induction in all cell types 
after 3 days of drug exposure.
When cells were treated with 5 µg/ml CDV, a 
difference in DNA damage induction between treated 
and untreated tumor cells was detected for HPV16+ cells 
(SiHa and SCC-147) (p < 0.05) and C33A cells (p < 0.01) 
but not for HeLa, SCC-120 and HaCaT cells (Figure 8B). 
At a CDV concentration of 50µg/ml, a significant 
difference in DNA damage between treated and untreated 
cells was observed for the different tumor cell lines 
tested (Figure 8B). In contrast to tumor cells, normal 
cells exposed or not to 5 or 50 µg/ml of CDV showed no 
differences in the percentage of cells with DNA damage 
(Figure 8C).
A negligible amount of γ-H2AX was found in 
untreated cells and this intrinsic γ-H2AX can vary among 
cell lines [34]. Therefore, the percentage of cells with 
DNA damage in untreated cells was subtracted from that 
of CDV-treated cells in order to compare the different cell 
types. The comparison of CDV-induced DNA damage in 
tumor cell lines versus normal cells is shown in Figure 8D. 
Figure 6: AtM protein expression after cdV exposure. Protein extracts were obtained at 3, 5 and 7 days of no treatment or 
treatment with 50 µg/ml CDV. Afterwards, Western blotting was performed using anti-ATM antibody and anti-actin antibody as a loading 
control. The amount of ATM relative to actin is shown in arbitrary units (AU) for all the cell lines. For each blot, the sum of intensity values 
was calculated and used for normalization of the values per blot. Statistical significance was indicated as follows: p < 0.05 (*). Values are 
shown as mean of minimum 3 experiments and SEM.
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SiHa, C33A and HaCaT (in contrast to the other tumor cells) 
showed higher amounts of DNA damage than PHKs after 
5 µg/ml CDV treatment (Figure 8D, up). All tumor cells, 
except for SCC-120, experienced more DNA damage than 
PET cells upon treatment with 5µg/ml CDV. In addition, at 
this dose of CDV, HEL cells underwent significantly less 
DNA damage than most tumor cells, except for SCC-120 
and SCC-147. When the DNA damage in normal versus 
tumor cells after treatment with 50 µg/ml of CDV was 
examined (Figure 8D, down), all tumor cells lines showed 
significantly higher DNA damage than HEL and PET 
cells. Only SiHa and C33A cells underwent significantly 
more DNA damage than PHKs at the highest CDV 
concentration tested. (except for SCC-120 and HaCaT) 
Flow cytometric analysis using propidium iodide 
(PI) and γ-H2AX staining showed that CDV-induced 
DSBs were present in each phase of the cell cycle (Data 
not shown). Thus, tumor cells in all phases of the cell 
cycle were equally sensitive to DNA damage. 
Finally, the CC50 values and the levels of CDV 
incorporation and drug-induced DNA damage were 
compared to detect potential correlations. A positive 
Figure 7: Phospho-AtM protein expression after cdV exposure. Protein extracts were obtained at 3, 5, 7 and 10 days of 
no treatment or treatment with 50 µg/ml. Afterwards, Western blotting was performed using anti-phospho-ATM antibody and anti-actin 
antibody as a loading control. The amount of phospho-ATM relative to actin is shown in arbitrary units (AU) for all the cell lines. For each 
blot, the sum of intensity values was calculated and used for normalization of the values per blot. Statistical significance was indicated as 
follows: p < 0.05 (*); p < 0.01 (**); p < 0.001 (***). Values are shown as mean of minimum 3 experiments and SEM.
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Figure 8: DNA damage induced by CDV by means of γ-H2AX analysis. Cells were seeded in culture flasks and 24 h later treated 
with 5 or 50 µg/ml of CDV. At 3 days post treatment, cells were trypsinized and permeabilized and fixed. Anti-γ-H2AX antibody was used 
to measure DNA damage by means of flow cytometry. (A) DNA damage at increasing CDV concentration in SiHa cells. (b) Untreated 
versus CDV treated tumor cells. (c) Untreated versus CDV treated normal cells. (d) Comparison of the DNA damage in tumor cell lines 
and normal cells, 3 days after treatment with 5 µg/ml or 50 µg/ml of CDV. In Figure D, a bar was drawn to indicate only a significant 
difference between two results. Statistical significance was indicated as follows: p < 0.05 (*); p < 0.01 (**); p < 0.001 (***); p < 0.0001 
(****). Values are shown as mean of minimum 3 experiments and SEM.
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correlation (p < 0.05) between CDV incorporation into 
DNA and DNA damage was found (Figure 9A) while there 
was no correlation between CC50 values and DNA damage 
(Figure 9B). 
dIscussIon
The antiproliferative effects of CDV were studied 
in nine HPV+, six HPV− cell lines (including cervical 
carcinoma and HNSCC) and three different normal cell 
types (PHKs, HEL and PET cells). Tumor cells proved 
to be more responsive to CDV antiproliferative activities 
than normal cells, as indicated by the lower CC50 
values obtained for the tumor cell lines. Here we have 
demonstrated that CDV is also active against HNSCC 
regardless of HPV status. The growth of PHKs was 
relatively more inhibited by CDV in comparison with the 
two other tested normal cells (HEL and PET), which could 
be explained by the fact that keratinocytes were artificially 
grown in a monolayer causing stress to these cells that are 
programmed to differentiate. 
Our results show that the antiproliferative activity 
of CDV is time- and dose-dependent, as shown previously 
[23]. Interestingly, a decrease in CC50 values in function 
of time was not found for other anti-tumor drugs such as 
cytarabine and 5-fluorouracil [23]. Although differences 
in response to CDV were detected among the various 
cell lines, these differences were not related to HPV 
status nor to tumor type (i.e. originating form cervical 
or head and neck tissues), indicating that CDV may be 
considered a broad-spectrum anti-tumor agent. Hadaczek 
et al. also showed that CDV inhibits glioblastoma both 
in vitro and in vivo, regardless of the presence of human 
cytomegalovirus (HCMV) [25], however a role for HCMV 
in the pathogenesis of glioblastoma is controversial [35]. 
It was previously shown that the in vitro and in vivo 
antiproliferative activities of CDV against nasopharyngeal 
carcinoma (which is driven by Epstein-Barr virus) were 
not due to inhibition of the viral DNA polymerase [27]. 
Furthermore, the activity of CDV against polyomavirus 
(PyV)-induced hemangioma in vivo could not be explained 
by an antiviral mechanism [26]. 
The correlation between CC50 values and doubling 
time indicates that the selectivity of CDV may be 
explained, at least in part, by a more potent inhibition of 
cell growth on fast proliferating cells (tumor cells) than 
on normal cells (which have slower proliferation rates). 
When the normal cells were excluded from the analysis, a 
significant correlation between CC50’s and doubling time 
was only observed at day 3 post-treatment but not at later 
time points. Spanos et al. described a correlation between 
CDV antiproliferative activities and doubling time in 
HNSCC after 4 days of treatment [36]. 
CDV selectivity for tumor cells could also be 
explained by a differential metabolism of the drug in 
malignant versus normal cells [37]. In all the cell types 
tested here, unmetabolized CDV and CDVp-choline were 
the most abundant fractions detected, what is in agreement 
with previous data on CDV metabolism [32]. Our findings 
indicate that a substantial amount of the administered CDV 
is not metabolized. Furthermore, the long half-life (87 h) 
of CDVp-choline [38] could explain its high abundance in 
the cells. The monophosphate form (CDVp), which has the 
shortest half-life (24 h), was the least abundant metabolite. 
Among the cell lines evaluated, HaCaT displayed a 
significantly lower sum of CDV metabolites, which could 
be attributed to changes in uptake and/or efflux of CDV, 
rather than to a difference in drug metabolism, since the 
amount of parent CDV was also lower in HaCaT than 
in the other cells. The higher levels of total metabolites 
in normal cells (PHK and PET) may be due to a higher 
activity of the enzymes responsible for CDV activation 
and/or more efficient drug uptake by these cells. However, 
CDV incorporation into DNA was lower in normal cells 
than in transformed cells. One can hypothesize that 
normal cells are able to remove incorporated CDVpp 
while transformed cells have alterations in their DNA 
damage repair mechanisms impeding drug excision. On 
the other hand, tumor cells proliferate faster than normal 
cells and therefore can incorporate more CDVpp. This 
last hypothesis is supported by the correlation between 
doubling time and CDV incorporation into DNA.
Induction of DNA damage may be an additional 
factor in the selectivity of CDV for tumor cells since 
normal cells are capable of repairing DNA damage while 
tumor cells often lack this capability [7]. The E6 and E7 
HPV oncoproteins override the G1/S-phase checkpoint 
hampering DNA damage repair in HPV+ transformed cells 
[5, 6]. Previous publications also suggested that HPV+ 
cells are more sensitive to radiation due to an impaired 
DNA damage response [39, 40]. Our experiments show 
that the failure of HPV+ cells to repair DNA damage 
does not occur at the beginning of the homologous 
recombination repair pathway since increase in phospho-
ATM after CDV treatment was found in all HPV+ cells. 
The augmentation of phospho-ATM in CDV-treated cells 
is in line with a previous gene expression analysis of PHKs 
[32], suggesting that induction of DSBs and activation of 
DNA DSB repair by homologous recombination occurs 
following CDV treatment.
Because phospho-ATM levels were elevated in all 
cell lines exposed to CDV (including normal cells), DSBs 
were quantified by measuring γ-H2AX. Importantly, in 
tumor cells there was significantly more DNA damage in 
CDV-treated than in untreated cells, which was not the 
case in normal cells. Furthermore, a statistically significant 
difference in induction of DNA damage was seen between 
most of the tumor cell lines and normal cells, as evidenced 
by γ-H2AX levels. Induction of DSBs by CDV was not 
linked to HPV positivity nor tumor type (cervical or head 
and neck), similar to CDV antiproliferative effects and 
drug incorporation into DNA. Nevertheless, no correlation 
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between DNA damage and CDV antiproliferative effects 
were observed suggesting that the mode of action of CDV 
cannot be solely explained by induction of DNA damage. 
Regarding CDV antiproliferative effects, SiHa 
cells (HPV16+ cervical carcinoma) proved to be the most 
sensitive among all the tumor cell lines evaluated in this 
study. Even though H2AX phosphorylation in CDV-exposed 
SiHa and C33A cells was comparable, C33A showed higher 
CC50 values than SiHa. HeLa cells presented higher CC50 
values than SCC-120 and HaCaT cells, but had more DNA 
damage after CDV exposure than SCC-120 and HaCaT 
cells. One can hypothesize that induction of DNA damage 
would lead to a decrease in CC50 values, unless the DNA 
damage is repaired. When the two tumor cell lines showing 
the lowest DNA damage (i.e. HaCaT and SCC-120) 
were excluded from the analysis of CC50’s and DNA 
damage, a significant  correlation (p < 0.05) between DNA 
damage and antiproliferative effects was found (Data not 
shown). These data suggest that HaCaT and SCC-120 cells 
are capable of (partially) repairing DNA damage although 
these cells were also shown to be sensitive to CDV. Taken 
together, our findings indicate that CDV antiproliferative 
activities are due to the induction of DNA damage but in 
contrast to most chemotherapeutics, additional effects can 
be deduced. Induction of apoptosis, cell cycle arrest or an 
increase in tumor suppressors such as p53, pRb or p21, 
which have been already described for CDV-treated HPV+ 
cells, could be a consequence of CDV incorporation into 
DNA [41]. However, activation of inflammatory responses 
(such as “NF-κB signaling” and “acute phase response”), 
retinoid X receptor pathways and Rho GTPase pathways 
among others should be taken into account to explain CDV 
antiproliferative activities [32].
One would expect no ATM phosphorylation in 
normal cells since there is no phosphorylation of H2AX 
in normal cells following 3 days of CDV treatment. 
However, in all the normal cells (PHK, HEL and PET) a 
significant enhancement of phospho-ATM was observed 
after 3, 5 and 7 days of CDV treatment. This discordance 
may be explained by the fact that ATM is not used as a 
marker for DSBs because it is not correlated with the 
amount of DSBs (ATM only needs 8 breaks per cell in 
Figure 9: correlation between cc50 values, dnA damage and cdV incorporation at day 3 post-treatment. Correlations 
between (A) DNA damage and CDV incorporation and (b) CC50 values and DNA damage were evaluated with the Pearson correlation 
coefficients. A linear regression line was drawn when a significant correlation was present.
Oncotarget47314www.impactjournals.com/oncotarget
order to be phosphorylated) [42]. In contrast, the intensity 
of γ-H2AX immunofluorescence was shown to correlate 
with the frequency of DSBs [34]. For this reason γ-H2AX 
was used in our studies as a quantitative marker for DSBs. 
We assume that CDV causes DSBs in normal cells that 
are sensed by ATM and then repaired by DNA repair 
mechanisms. Even a small amount of DSBs would be 
sufficient to activate ATM but it would not be high enough 
to cause a significant difference in phosphorylation of 
H2AX. After an initial step of ATM phosphorylation, the 
existing damage is evaluated [43] and if the damage is 
repaired, phospho-ATM is dephosphorylated by Wip1 
and PP2A. In case of persistent DNA damage, there is 
a new peak of ATM-phosphorylation [9, 43]. Thus, in 
contrast to normal cells, phospho-ATM may accumulate 
in tumor cells after CDV exposure because of persistent 
DNA damage. The accumulation of breaks in tumor cells 
is deduced from the high amount of cells with γ-H2AX 
immunofluorescence. To conclude, the levels of γ-H2AX 
and phospho-ATM do not evolve in parallel because 
γ-H2AX is correlated with the amount of DSBs whereas 
activation of ATM takes place even when there is only a 
limited amount of DSBs and does not correlate with the 
amount of DSBs [33].
A discrepancy between γ-H2AX and phospho-
ATM was also observed for C33A cells that showed a 
high amount of phosphorylated H2AX upon 3 days of 
50 µg/ml CDV treatment while no significant increase 
of phospho-ATM was observed at this time point. This 
could be explained by the fact that in response to DNA 
damage, all three phosphatidylinositol 3-kinase-related 
kinases (PIKKs): ATM, ataxia telangiectasia and Rad3-
related protein (ATR), and DNA-dependent protein kinases 
(DNA-PKcs) can phosphorylate H2AX as previously 
reported following DNA damage caused by ionizing 
radiation [44]. Additionally, it is not yet clear which PIKK 
is responsible for H2AX phosphorylation during apoptosis. 
This is consistent with formerly reported data showing that 
UV-induced replication stress triggers activation of ATR 
and DNA PKcs rather than ATM [45]. Most publications, 
however, point out that the induction of DSBs triggers 
phosphorylation of H2AX by ATM [33, 46, 47].
In conclusion, we have shown here the 
antiproliferative effects of CDV against cervical carcinoma 
and HNSCC HPV+ and HPV− cells. CDV antiproliferative 
effects were correlated with drug incorporation into DNA. 
Moreover, CDV incorporation was correlated with DNA 
damage, indicating that CDV incorporation causes DNA 
damage. However, the anti-tumor effect of CDV cannot 
be explained exclusively by DNA damage, since no 
correlation was observed between DNA damage and CDV 
antiproliferative effects. These data support the concept of 
CDV as a general anti-cancer agent not restricted to HPV+ 
tumor cells [25–28, 48]. Our results contribute to a better 
insight into the selective mechanism of CDV anti-tumor 
activities which is crucial for the development of new 
strategies to treat HPV-associated neoplasias that cannot 
be cured with standard therapies. In addition, our work 
sets up the basis for further investigations on the mode of 
action of CDV and on the DNA repair mechanism.
MAterIAls And MetHods
cells
HPV+ and HPV− cell lines derived from cervical 
carcinoma or head and neck squamous cell carcinoma 
(HNSCC) were compared to spontaneously transformed 
keratinocytes (HaCaT), primary human keratinocytes 
(PHKs), primary epithelial tonsil (PET) cells and human 
embryonic lung (HEL) fibroblasts. Cervical cancer 
cell lines: SiHa (HPV16+) (ATCC HTB-35™), HeLa 
(HPV18+) (ATCC CCL-2™), Caski (HPV16+) (ATCC 
CRL-1550) and C33A (HPV−) (ATCC HTB-31™) were 
obtained from ATCC (Manassas, USA). CK1 (HPV33+) 
cells were kindly provided by Jaques Piette (Departement 
of Life Sciences, University of Liège, Belgium). The 
HNSCC SCC-9 (ATCC CRL-1629™) and SCC-4 (ATCC 
CRL-1624™) (both HPV-) were obtained from ATCC; 
93VU147T later called SCC-147 (HPV16+) and 93VU120 
later called SCC-120 (HPV-) were kindly provided by 
Mario Hermsen (Department of Otolaryngology, Instituto 
Universitario de Oncología del Principado de Asturias 
(IUOPA), Spain); UM-SCC-47 (HPV16+), UM-SCC-104 
(HPV16+) and UM-SCC-38 (HPV-) were purchased from 
the University of Michigan (USA); UT-SCC-45 (HPV33+) 
and UD-SCC-2 (HPV16+) were kindly provided by 
Reidar Grénman (Dept. of Otorhinolaryngology-Head 
and Neck Surgery Turku University Central Hospital, 
Finland) and Prof. Thomas Hoffman (Department of 
Otorhinolaryngology, University hospital Ulm, Baden-
Württemberg), respectively. HPV-, in vitro spontaneously 
transformed keratinocytes from histologically normal 
skin (HaCaT) were kindly provided by F. De Marco 
(Laboratory of Virology, Regina Elena Institute for Cancer 
Research, Rome, Italy). Human embryonic lung (HEL) 
fibroblasts (HEL-299: ATCC CCL-137) were grown 
in Earle’s minimum essential medium (MEM Earle’s, 
Life Technologies, Merelbeke, Belgium) containing 
8% fetal calf serum. PET and PHK were isolated from 
tonsils and from neonatal foreskins, respectively, as 
previously described [49] and cultured in Keratinocyte-
SFM Medium (Gibco, Life Technologies). All cancer cell 
lines were maintained in Dulbecco’s modified Eagle’s 
medium (Gibco, Life Technologies) except for SCC-4 
and SCC-9 which were grown in Dulbecco’s modified 
Eagle’s medium plus F12 (Gibco, Life Technologies). All 
media were supplemented with 1% non-essential amino 
acids (MEM NEAA, Gibco by Life Technologies), 1% 
sodium pyruvate 100 mM (Gibco by Life Technologies), 
1% Penicillin/ Streptomycin/ Glutamine 100× (Gibco by 
Life Technologies) and 1% HEPES 1M (Gibco by Life 
Technologies). 
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Presence of HPV genome in the different cell 
lines
The presence or absence of the HPV genome in all 
the aforementioned cells was confirmed by performing a 
specific PCR. DNA was extracted with a QIAamp DNA 
mini kit (Qiagen Benelux, Netherlands) following the 
instructions of the manufacturer, followed by PCR to 
confirm whether the cell lines were HPV16+, HPV18+, 
HPV33+ or HPV−. Specific primers for each HPV type 
(supplementary Table 1) were purchased from Eurofins 
(Brugge, Belgium).
Antiviral compound
Cidofovir (CDV) or (S)-HPMPC, [(S)-1-[3-
hydroxy-2-(phosphonomethoxy)propyl]cytosine] was 
obtained from Gilead Sciences (Foster city, Ca, USA). It 
was prepared in PBS at a stock concentration of 10 mg/
ml. Radiolabeled [5-3H]-CDV (1mCi/ml; specific activity: 
25 Ci/mmol) was purchased from Moravek Biochemicals 
(Brea, CA, USA) and stored at −20°C in ethanol/water 1:1. 
Antiproliferative effects
Cells were seeded in 96-well microtiter plates at an 
amount ranging from 2.5 × 103 to 6 × 103 cells per well, 
determined for each cell line (2.5 × 103 for SiHa, HeLa, 
C33A, SCC-120, SCC-9, UM-SCC-47 and UM-SCC-38; 
3 × 103 for HaCaT; 3.5 × 103 for HEL; 4 × 103 for Caski, 
SCC-4, CK1, UT-SCC-45 and UD-SCC-2; and 6 × 103 for 
SCC-147, PHK, PET and UM-SCC-104). After 24 hours, 
medium containing different concentrations of CDV, 
ranging from 0.05 µg/ml to 200 µg/ml, was added to the 
cells (in duplicate). After 3, 5, 7 and 10 days, the cells 
were trypsinized and counted with a Coulter counter. The 
antiproliferative effects were expressed as the compound 
concentration needed to inhibit cell growth by 50% (CC50). 
In vitro growth rate
The doubling time (DT) of the different cell lines 
was determined in 96-well microtiter plates. At several 
time points, the number of cells was determined with a 
Coulter counter. DT was calculated with the formula: DT 
= (t2-t1)/(log2N2-log2N1), where t1 and t2 are the times (in 
hours) at which the cells were counted, and N1 and N2 are 
the cell numbers at times t1 and t2.
Metabolism and incorporation of cdV into dnA
Cells were grown in 75 cm2 culture flasks for 24 
hours before adding unlabeled CDV combined with 
[5-3H]-CDV at a final concentration of 50 μg/ml and 10 
μCi per flask. After 3 days of incubation, samples for 
HPLC analysis were prepared by methanol extraction as 
described previously [32]. The soluble fraction of this 
MeOH extraction (200 µl) was injected onto a HPLC 
system equipped with an anion-exchange Partisphere SAX 
column (Hichrom limited, Berkshire, UK) and separation 
was performed with a gradient of two phosphate buffers; 
5 mM NH4H2PO4, pH 6.5 and 0.3 M NH4H2PO4, pH 
6.5 at a flow rate of 2 ml/min. One-minute fractions of 
the eluate were collected, mixed with HiSafe 3 cocktail 
(Perkin Elmer, Massachusetts, USA) and analyzed for 
radioactivity in a scintillation counter. The retention 
times of CDV and its metabolites were: 3 min for CDVp-
choline, 5 min for CDV, 15 min for CDVp, and 19 min 
for CDVpp. To determine the incorporation of CDV into 
nucleic acids, the methanol-insoluble pellets were digested 
with 500 µl 5N NaOH during 24 hours at 37°C. The 
solution was neutralized with 500 µl 5N HCl, then mixed 
with HiSafe 3 cocktail and analyzed for total radioactivity. 
Protein extract preparation and immunoblotting
Protein extracts were obtained at 3, 5 and 7 days of 
no treatment or treatment with 50 µg/ml CDV. Whole cell 
lysates were prepared in Ripa buffer (Thermo Scientific, 
Brussels, Belgium) containing protease (Complete Mini, 
EDTA-free, Sigma-Aldrich, Diegem, Belgium) and 
phosphatase inhibitors (Active Motif, La Hulpe, Belgium). 
Protein concentrations were measured by the BCA assay 
(Thermo Scientific). Separation of proteins was performed 
with SDS-PAGE. Western Blot analysis was performed 
with anti-phospho-ATM (Ser1981) clone 10H11.
E12 (Millipore, Billerica, MA, USA) and anti-ATM 
antibody (ab32420, Abcam, Cambridge, UK). Relative 
quantification was performed using actin (ab3280, Abcam) 
as a loading control. For each blot, the sum of intensity 
values was calculated and used for normalization of the 
values per blot. 
dnA damage induced by cdV by means of 
γ-H2AX analysis
DNA damage was evaluated by means of a 
FlowCellect TM cell cycle Checkpoint H2A.X DNA 
damage kit (Millipore). Briefly, cells were seeded in 
culture flasks for 24 hours before adding 5 or 50 µg/ml 
CDV. After three days of incubation, the cells were fixed, 
permeabilized and stained with propidium iodide and 
anti-γ-H2AX antibody. Samples were read with a BD 
FACSCalibur.  
statistical analysis
Statistical analyses were performed with GraphPad 
Prism 6 software (GraphPad Software Inc., La Jolla, 
CA, USA). To evaluate the antiproliferative effects 
of CDV over time and to compare treated cells with 
untreated cells for DNA damage, a paired t-test was used. 
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Unpaired t-test was used to compare different cell lines 
for CC50 values, DT, metabolites, incorporation into DNA, 
and DNA damage. Pearson correlations were assessed 
comparing DT and CC50; CC50 and DNA damage; CC50 
and DNA incorporation and DNA damage and DNA 
incorporation. P < 0.05 was considered as statistically 
significant.
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